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Second messenger cascade specificity and pharmacological
selectivity of the human P2Y1-purinoceptor
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1 The coding sequence of the P2YI-purinoceptor was cloned from a human genomic library.
2 The open reading frame encodes a protein of 373 amino acids that is 83% identical to the previously
cloned chick and turkey P2YI-purinoceptor and is >95% homologous to the recently cloned rat, mouse,
and bovine P2YI-purinoceptors.
3 The human P2YI-purinoceptor was stably expressed in 1321N1 human astrocytoma cells using a
retroviral vector. Although the P2Y1-purinoceptor agonist, 2MeSATP, had no effect on inositol
phosphate accumulation in 1321N1 cells infected with the control virus, this agonist markedly stimulated
inositol phosphate accumulation in cells infected with the P2YI-purinoceptor virus. No effect of
2MeSATP on cyclic AMP accumulation was observed in P2Y1-receptor-expressing 1321N1 cells.
4 The pharmacological selectivity of 18 purinoceptor agonists was established for the expressed human
P2YI-purinoceptor. 2MeSATP was more potent than ATP but less potent than 2MeSADP. ADP also was
more potent than ATP. A similar maximal effect was observed with most agonists tested. However, a,f,-
MeATP had no effect and 3'-NH2-3'-deoxyATP and A2P4 were partial agonists. The order of potency of
agonists for activation of the turkey P2Y1-purinoceptor, also stably expressed in 1321N1 cells, was
identical to that observed for the human P2YI-purinoceptor.
5 C6 glioma cells express a P2Y-purinoceptor that inhibits adenylyl cyclase but does not activate
phospholipase C. Expression of the human P2Y1-purinoceptor in C6 cells conferred 2MeSATP-stimulated
inositol lipid hydrolysis to these cells. The phospholipase C-activating human P2Y,-purinoceptor could be
delineated from the endogenous P2Y-purinoceptor of C6 glioma cells by use of the P2-purinoceptor
antagonist, PPADS, which blocks the P2YI-purinoceptor but does not block the endogenous P2Y-
purinoceptor of C6 cells. P2-purinoceptor agonists also exhibited differential selectivities for activation of
these two P2Y-purinoceptors.
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Introduction
P2-purinoceptors for extracellular adenine nucleotides origin-
ally were subclassified into the P2X- and P2Y-subtypes on the
basis of differential contractile responses of various tissues to a
series of hydrolysis resistant analogues of ATP (Burnstock &
Kennedy, 1985). Further delineation of putative P2-pur-
inoceptor subtypes has evolved on the basis of differences in
selectivity of various nucleotides for stimulation of certain
responses. For example, the existence of P2u-purinoceptors
was initially proposed on the basis of the agonist activity of
UTP and ATP at this receptor(s) (Dubyak & El-Moatassim,
1993), and the P2T-purinoceptor(s), which is activated by ADP
but antagonized by ATP, has been widely studied in platelets
(Hourani & Cusack, 1991).
Unambiguous delineation of P2-purinoceptor subtypes has
followed from the cloning and expression of functional protein
from nucleotide sequences encoding these receptors. Four
subtypes of P2x-purinoceptors have been cloned and shown by
functional expression to exhibit the general pharmacological
and electrophysiological properties expected of these ligand-
gated ion channel receptors (Brake et al., 1994; Valera et al.,
1994; Abbracchio & Burnstock, 1994; Chen et al., 1995). As-
sociation of pharmacological selectivity with proteins of
known structure also has been made for members of a group of
P2-purinoceptors that regulate physiological responses by ac-
tivation of G-protein-regulated signalling responses (Lustig et
al., 1993; Webb et al., 1993; Parr et al., 1994; Filtz et al., 1994;
Lazarowski et al., 1995).
Our laboratory has examined in detail the second messenger
signalling properties and pharmacological selectivity of a P2-
purinoceptor on turkey erythrocytes. This receptor, designated
the P2YI-purinoceptor, has been cloned from chick (Webb et
al., 1993) and turkey (Filtz et al., 1994) and stably expressed in
a null cell line (Filtz et al., 1994). The pharmacological se-
lectivity of the turkey P2Y1-purinoceptor as natively expressed
in turkey erythrocytes (Burnstock et al., 1994; Boyer et al,
1994; 1995) or heterologously expressed in a mammalian cell
line (Filtz et al., 1994) is very similar to the pharmacological
profile of responses previously studied in mammalian tissues,
e.g. a P2y-like purinoceptor on guinea-pig taenia coli (Burn-
stock et al., 1994). However, the pharmacological selectivity of
a cloned mammalian P2y-purinoceptor has not been reported
in detail. As such, we have cloned the human P2Y,-pur-
inoceptor and have expressed and extensively characterized the
pharmacological and second messenger signalling properties of
this receptor.
Methods
Cloning of the human P2y,-purinoceptor
Using 0.36 pg of rat genomic DNA as template, a 702 bp
fragment encoding the rat homologue of the turkey P2Y,-pur-
inoceptor was generated by polymerase chain reaction with
degenerate primers (upstream, 5'-TGGATGTT(TC)GTTTT-
(TC)CA(TC)ATG-3', and downstream, 5'-GAGATCTA-
GATCACAAACTGGTGTCCCCGTT-3') based on the se-
quence of the turkey P2YI-purinoceptor, followed by re-
amplification with an internal upstream primer (5'-TTCCTC-
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AC(CG)TGCAT(AC)AGCGTGCA-3') and the same down-
stream primer. The fragment was radiolabelled (Pharmacia
Radiolabeling Kit) and used to screen a lambda Zap II human
brain cDNA library (Stratagene). One positive clone, obtained
from 1 x 106 screened, was excised and sequenced by the di-
deoxy chain termination method (Sequenase II, USB). The
clone was 1543 bp in length and contained an open reading
frame from nucleotides 1 to 972. This sequence, which was
82% homologous with bases 118 to 1089 of the turkey P2Y1-
purinoceptor sequence, was incomplete at the 5' end. A 300 bp
probe, corresponding to the 5'-end of this cDNA clone, was
generated and used to probe a human genomic library (kindly
provided by Dr Beverly Mitchell). Two positive clones con-
taining large (> 10 kbp) inserts were obtained. The genomic
clones were amplified, and the ADNA was isolated and di-
gested with Sacl. A 2000 bp fragment containing the probe
sequence was identified in both A clones by Southern blotting,
and each fragment was subcloned and sequenced in both di-
rections. The genomic sequence corresponded exactly to the
cDNA sequence but also included 150 bp of additional 5' se-
quence containing an initiating methionine codon.
Expression of the P2y,-purinoceptor in 1321NJ cells
The coding sequence of the receptor was amplified with Pfu
DNA polymerase (Stratagene) using primers containing either
an EcoRI site (upstream primer) or a XhoI site (downstream
primer). This fragment was subcloned into the retroviral ex-
pression vector pLXSN, and the upstream primer was situated
such that 18 bp of 5' untranslated sequence was included in the
amplified product. Retrovirus conferring expression of P2Y,-
purinoceptor was produced by calcium phosphate transfection
of the murine packaging cell line PA317 with pLXSN vectors
containing the human or turkey receptor sequences as de-
scribed by Olsen and colleagues (Comstock et al., 1995). After
a 2 day incubation at 320C in the presence of 5 mM butyrate,
the virus-containing supernatant was removed, filtered, and
incubated for 2 h with 1321N1 cells in the presence of
8 Mg ml-' polybrene. Infected 1321N1 cells were selected for
neomycin resistance for two weeks in the presence of
600 Mg ml-' G-418. Comparisons of the pharmacological se-
lectivity of human and turkey P2Y,-purinoceptors were made in
these neomycin-resistant cell populations. Retroviral infection
of C6 rat glioma cells was performed similarly with
800 pg ml-' G418 for selection.

















Quantification of inositol lipid hydrolysis
Functional responses to purinoceptor agonists were assessed
by measurement of inositol phosphate accumulation as de-
scribed by Lazarowski & Harden (1994). Briefly, 131N1 cells
stably expressing the human P2Y,-purinoceptor were plated at
a density of 2 x I05 cells/well in 12 well plates and assayed three
days after subculture. The growth medium (DMEM with 5%
FBS and 600 pg ml-' G418) was replaced with 0.5 ml of ser-
um-free, inositol-free medium supplemented with 2 pCi ml-'
of [3H]-myo-inositol (20 Ci mmol-'; American Radiolabeled
Chemicals). The culture plates were removed from the in-
cubator 24 h later, the medium was supplemented with 50 p1
250 mM HEPES, pH 7.4, and the plates were placed in a 370C
water bath. Drug challenges were initiated by addition of
agonist and 10 pM LiCl in HEPES-buffered, inositol-free
DMEM. After a 10 min incubation the medium was aspirated
and the assay terminated with 500 p1 of cold 5% TCA. The
TCA-containing supernatant was extracted three times with
ether and inositol phosphates were isolated by chromato-
graphy on Dowex AG1-X8.
Quantitation of cyclic AMP accumulation
Cells were prepared essentially as described for the inositol
phosphate assay except the medium was replaced with normal
DMEM 24 h prior to assay and this was supplemented with
1.0 pCi ml-' [3H]-adenine (25 Ci mmol'-, Amersham) for 2 h
before assay. Cells were preincubated with isobutylmethyl
xanthine (IBMX, 0.2 mM, final concentration) for 10 min
prior to a 10 min incubation with agonists. Drug challenges
were terminated by aspiration of the medium and addition of
5% TCA. The extract was applied directly to Dowex and
alumina columns for isolation of [3H]-cyclic AMP.
Results
The sequence and pharmacological selectivity have been re-
ported for a P2Y-purinoceptor cloned from chick (Webb et al.,
1993) or turkey brain cDNA libraries (Filtz et al., 1994). By
use of primers based on the turkey and chick P2y,-pur-
inoceptor sequences, a sequence encoding a portion of the rat
homologue of this receptor was amplified from rat genomic







Figure 1 Comparison of the predicted amino acid sequences of the human, turkey and rat, P2y,-purinoceptor.
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isolate a partial cDNA clone of this receptor from a human
brain cDNA library, and this partial cDNA subsequently was
used to isolated the complete coding sequence of the human
homologue of the avian P2YI-purinoceptor from a human
genomic library (Figure 1). An open reading frame of 1119
nucleotides encoding 373 amino acids (calculated Mr =
42,000) was identified. The human P2Y1-purinoceptor sequence
is 79% identical at the nucleic acid level and 83% identical at
the amino acid level to the turkey P2YI-purinoceptor sequence
(362 amino acids). In addition to low homology in the amino
terminal domain, the human sequence contains an 11 amino
acid insert near the amino terminus that is absent in the avian
sequence. This insert also is present in the sequences of the rat
(Tokuyama et al., 1995), mouse (Tokuyama et al., 1995), and
bovine (Henderson et al., 1995) homologues of the P2Y1 pur-
inoceptor, which have been reported during the completion of
this work on the human P2Y1-purinoceptor. Differences in
amino acid sequence of the human versus avian P2Y,-pur-
inoceptor also occur elsewhere, particularly in the predicted
fourth and fifth transmembrane-spanning domains, although
several of these are conservative changes. In contrast, the hu-
man P2YI-purinoceptor sequence is approximately 95% iden-
tical at the amino acid level to the rat (Tokuyama et al., 1995),
mouse (Tokuyama et al., 1995), and bovine (Henderson et al.,
1995) P2YI-purinoceptors.
The human P2YI-purinoceptor was stably expressed in
1321N1 human astrocytoma cells after construction of a ret-
roviral vector. The P2Y-purinoceptor agonist, 2MeSATP, had
no effect on inositol phosphate accumulation in wild-type
1321N1 cells or in 1321N1 cells infected with an empty retro-
viral vector (Figure 2). However, 2MeSATP markedly stimu-
lated inositol phosphate accumulation in cells infected with
retrovirus containing the coding sequence of the human P2y1-
purinoceptor.
The pharmacological selectively of the stably expressed
human P2YI-punnoceptor was examined by use of 18 nucleo-
tide analogues. The relative potency of these agonists for sti-
mulation of inositol phosphate accumulation was consistent
with the order of potency expected for a P2y-purinoceptor
(Figure 3 and Table 1). As initially observed by Burnstock &
Kennedy (1985) for P2Y-purinoceptors, the 2-thioether deri-
vative of ATP was more potent than ATP or other ATP
analogues. However, 2MeSADP was more potent than 2Me-
SATP as were other diphosphate analogues compared to their
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Figure 2 Inositol phosphate responses in 1321N1 cells expressing the
human P2y1-purinoceptor. 1321N1 cells were either mock-infected
(wild type), infected with control retroviral vector pLXSN (vector),
or infected with this same retroviral vector containing DNA encoding
the human P2yI-purinoceptor (hP2y1-R). Following selection of
infected cells with G-418, all three cell populations were examined
for receptor-stimulated inositol phosphate accumulation in the
presence of either 1 gm 2MeSATP (solid columns) or 1 mm carbachol
(stippled columns); basal (open columns). The data are the mean +
s.e.mean of four experiments performed in triplicate.
maximal effect was observed with most of the agonists tested.
However, the P2X-purinoceptor-selective agonist, a,fl-methy-
lene ATP, had no effect on inositol phosphate accumulation,
and 3'-NH2-3'-deoxyATP and A2P4 exhibited only partial
agonist activities (Figure 4). This lack of full agonist effect of
these two compounds was not a consequence of their low
potency since AppNHp exhibited low potency but was a full
agonist. The previously cloned turkey P2Y1-purinoceptor (Filtz
et al., 1994) was also stably expressed in 1321N1 cells using the
retroviral expression system, and the relative order of po-
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Figure 3 Pharmacological selectivity of the human P2yI-purinocep-
tor. Inositol phosphate responses to a series of purinoceptor agonists
were examined as described in Methods. The data shown are the
combined results of three to five independent experiments for each
agonist. Results in each experiment were normalized to the maximal
response of 2MeSATP in that experiment to facilitate combination of
data from different experiments. Data are shown for 2MeSADP (0),
2MeSATP (0), ADP (O), ADPfS (O), ATPyS (U), ATP (*).
a,,BMeADP (*), and Lx,#MeATP (x).



























































EC50 values are shown (nM) for the stimulation of inositol
phosphate accumulation by purinoceptor agonists in
1321N1 cells infected with retrovirus encoding either the
human or turkey P2yI-purinoceptors. Values are the
mean+s.e.mean of three independent determinations per-
formed simultaneously on both cell lines. The efficacies of
two partial agonists relative to 2MeSATP are indicated in
parentheses preceding the EC50 values. NE indicates no
effect at 100,000 nM.
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P2YI-purinoceptor homologues. The full agonists tested were
approximately two fold more potent at the turkey P2YI-pur-
inoceptor than at the human homologue of this receptor. Thus,
both the order and the ratio of agonist potencies were essen-
tially identical for the two P2YI-purinoceptor homologues. Si-
milar agonist potencies also were observed whether they were
determined in assay incubation times of 1 min or 15 min. This
result suggests that hydrolysis of agonists does not influence
the EC50 values that were observed. 3'NH2-3'-deoxyATP and
A2P4 were partial agonists at both the human and avian P2y1-
purinoceptors but in contrast to the results with full agonists,
the potency observed for each of these partial agonists was the
same whether determined with the human or avian receptor.
One interpretation of these results is that a larger degree of
receptor reserve exists in 1321Nl cells expressing the turkey
P2YI-purinoceptor than in 1321N1 cells expressing the human
P2Y,-purinoceptor.
A P2y-purinoceptor that inhibits adenylyl cyclase but does
not activate phospholipase C, is endogenously expressed on C6
rat glioma cells (Boyer et al., 1993; 1994). To assess whether
the cloned human P2YI-purinoceptor also coupled to adenylyl
cyclase, we examined cyclic AMP accumulation in 1321N1
cells expressing this receptor. Although marked P2Y-pur-
inoceptor-promoted inositol lipid hydrolysis was observed,
2MeSATP caused neither stimulation nor inhibition of cyclic
AMP accumulation in 1321N1 cells expressing the human
P2YI-purinoceptor (Figure 5). The most parsimonious inter-
pretation of these results is that a P2Y-purinoceptor has been
cloned that couples to phospholipase C but not to adenylyl
cyclase. Alternatively, the second messenger signalling se-
lectivity of the P2Y-purinoceptor could be specific to the cell
type in which the receptor is expressed. To distinguish between
these two possibilities, the human P2Y1-purinoceptor was ex-
pressed in C6 cells to determine whether expression in this cell
line would result in a different second messenger signalling
phenotype. Infection ofC6 cells with human P2Y,-purinoceptor
retrovirus conferred an inositol phosphate response to analo-
gues of ATP that was not observed in wild type or in vector-
infected cells (Figure 6). In contrast, 2MeSATP-promoted in-
hibition of cyclic AMP accumulation was essentially indis-
tinguishable between wild type C6 cells and C6 cells expressing
the human P2Y1-purinoceptor (not shown).
P2-purinoceptor agonists and antagonists also were utilized
to distinguish between the human P2YI-purinoceptor stably
expressed in C6 cells and the adenylyl cyclase-linked P2y-pur-
inoceptor that is native to these cells. We previously have re-
ported that whereas the P2-purinoceptor antagonist, PPADS,










Cn) -10 -9 -8 -7 -6 -5 -4
log [Agonist] M
Figure 4 Demonstration of agents with partial agonist activity.
Inositol phosphate responses to partial and full agonists were
assessed in 1321N1 cells stably expressing the human P2y1-
purinoceptor. The data are normalized as in Figure 3. Data are
shown for 2MeSATP (0), 2ClATP (*), A2P4 (O), 3'-NH2-3'-dATP
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Figure 5 Effect of the human P2YI-purinoceptor on cyclic AMP
accumulation. Cyclic AMP accumulation was measured in 1321NI
cells expressing the human P2Y1-purinoceptor in the presence of
various concentrations of 2MeSATP and in the presence (0) or
absence (El) of 20juM isoprenaline and WpHM forskolin. The data are
shown from a single experiment, and are representative of results
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Figure 6 Inositol phosphate accumulation in C6 cells stably
expressing the human P2YI-purinoceptor. Inositol phosphate accu-
mulation was measured in C6 glioma cells stably expressing the
human P2Y1-purinoceptor. Assays were in the presence of vehicle
(open columns), 1pM 2MeSATP (solid columns), or 10pM A1F4-
(stippled columns). The data are the means+ s.e.mean from four
experiments.
purinoceptor of turkey erythrocytes, this drug has no effect on
the adenylyl cyclase-linked P2Y-purinoceptor of C6 glioma cells
(Boyer et al., 1994). Consistent with these previous results,
PPADS had no effect of P2Y-purinoceptor-promoted inhibition
of cyclic AMP accumulation in human P2Y1-purinoceptor-ex-
pressing C6 cells (Figure 7a). In contrast, PPADS antagonized
2MeSATP-stimulated inositiol phosphate accumulation under
the same conditions. Thus, 30 gM PPADS resulted in a 10 fold
shift to the right of the concentration-effect curve for 2Me-
SATP (Figure 7b). PPADS did not affect muscarinic receptor-
stimulated inositol phosphate accumulation in these cells (data
not shown), illustrating that PPADS is selective for the phos-
pholipase C-linked P2Y-purinoceptor over the adenylyl cyclase-
linked P2Y-purinoceptor endogenous to the C6 cell.
In addition to selective blockade by PPADS of 2MeSATP-
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human P2Y,-purinoceptor, the inositol phosphate and cyclic
AMP responses also were activated differently by certain
agonists (Figure 8a and b). For example, the order of potencies
of four agonists for stimulation of inositol lipid hydrolysis was
similar whether determined with 1321N1 or C6 cells expressing
the human P2YI-purinoceptor (compare Table 1 with Table 2).
These four drugs exhibited a different order of potency and, in
the case of 3'-NH2-3'-deoxyATP, a different efficacy, for P2y-
purinoceptor-promoted inhibition of adenylyl cyclase in C6
cells. These data strongly support the contention that the
cloned human P2Y1-purinoceptor is functionally, and therefore,
structurally distinct from the P2Y-purinoceptor subtype en-
dogenous to C6 rat glioma cells.
Discussion
Pharmacological characterization of P2-purinoceptors has
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Figure 8 Relative agonist potencies for the stimulation of inositol
phosphate and cyclic AMP responses in C6 glioma cells expressing
the human P2y1-purinoceptor. The relative potencies of 2MeSADP
(E), ADP (0), ADPfiS (A), and 3'-NH2-3'-deoxyATP (C>) were
determined for stimulation of inositol phosphate accumulation (a)
and inhibition of cyclic AMP accumulation (b) in C6 glioma cells
stably expressing the human P2y1 receptor. The data are presented as
percentage of maximal response to 1 gM 2MeSADP (a) or percentage
of isoprenaline-stimulated cyclic AMP accumulation (b).
Table 2 Agonist potencies for second messenger effects in
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Figure 7 Effect of a P2-purinoceptor antagonist on P2-purinoceptor-
promoted responses in C6 cells expressing the human P2y1-
purinoceptor. The cyclic AMP (a) and inositol phosphate (b)
responses to 2MeSATP were examined in the presence (N) and
absence (LI) of 30 gM PPADS in C6 gihoma cells stably expressing the
human P2y1-purinoceptor. The EC50 for 2MeSATP for inhibition of
cyclic AMP accumulation was 1+0.2 nm in the absence or in the
presence of PPADS. The EC50 of 2MeSATP for stimulation of
inositol phosphate accumulation was 13 + 2 nM in the absence of

















EC50 values of four agonists were determined for two
second messenger responses in C6 rat glioma cells
expressing the human P2yI-purinoceptor. Values (shown
in nanomolar+s.e.mean) are averages of three experiments
performed in triplicate.
and undefined P2-purinoceptors and by high levels of ectonu-
cleotidase activity in these tissues. Molecular cloning and
functional expression of the proteins that comprise the large
family of P2-purinoceptors provides a means of circumventing
these potential problems and associating drug selectivities with
receptor proteins of defined structure. Based on the original
report of Webb and coworkers (Webb et al., 1993) we pre-
viously cloned, expressed, and determined the pharmacological
selectivity of the turkey homologue of the P2YI-purinoceptor
(Filtz et al., 1994). This avian receptor sequence now has been
used to clone the first human homologue of a seven-trans-
membrane spanning receptor that exhibits the pharmacologi-
cal selectivity of the classically defined P2Y-purinoceptor.
The pharmacological selectivity of the human P2y,-pur-
inoceptor when expressed in a null cell line is remarkably si-
milar to that proposed by Burnstock & Kennedy (1985) in
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their original description of a P2Y-purinoceptor. 2MeSATP
was much more potent than ATP, and a,flMeATP was without
effect. The original classification of P2Y-purinoceptors did not
specifically consider the relative potency of ADP and analo-
gues of this diphosphate. However, our data with the avian
(Burnstock et al., 1994; Filtz et al., 1994) and now the human
P2YI-purinoceptor indicate that this receptor is also readily
activated by ADP and by ADP analogues at concentrations
typically lower than those necessary for activation by the
corresponding ATP analogues. A receptor that is activated by
ADP and referred to as a P2rpurinoceptor has been widely
studied in platelets (Hourani & Cusack, 1991). Although the
P2Y1-purinoceptor shares with the platelet P2T-purinoceptor the
capacity to be activated by ADP, these receptors can be dis-
tinguished readily by the action of ATP. ATP is a competitive
antagonist of the platelet purinoceptor but is a full agonist at
the human P2YI-purinoceptor.
The pharmacological selectivity previously determined for a
broad range of agonists for activation of the avian P2y-pur-
inoceptor closely matched the selectivity of these agonists for
activation of a P2Y-like receptor on guinea-pig taenia coli (Fi-
scher et al., 1993; Burnstock et al., 1994). Nonetheless, the true
relevance of the avian receptor to P2y-purinoceptors in mam-
malian tissues has been unclear. Data obtained with the cloned
and expressed human P2Y1-purinoceptor now place the avian
receptor in clearer context. The relative order of potency of a
large number of agonists at the human receptor matches the
order of potency of the same agonists at the avian receptor.
Thus, the turkey P2YI-purinoceptor is apparently an accurate
pharmacological model for a human P2Y-purinoceptor. Deli-
neation of the specific role of P2YI-purinoceptors in various of
the physiological responses that have been attributed to P2y-
purinoceptors, including the aforementioned response observed
in guinea-pig taenia coli, will be important to establish.
Not only was the pharmacological selectivity of the human
receptor the same as that of the avian P2Y1-purinoceptor, but an
identical specificity of second messenger signalling was ob-
served. This selectivity was established by stable expression of
the human receptor in two different cell lines. A cell line, 1321N1
human astrocytoma cells, that does not express a measurable
phospholipase C response to extracellular nucleotides has been
widely used by our laboratory and others to express stably P2-
purinoceptors. As we previously observed with the avian P2y1-
purinoceptor (Filtz et al., 1994), stimulation of inositol lipid
hydrolysis was observed in 1321N1 cells stably expressing the
human P2Y1-purinoceptor. In contrast, the potent P2Y-pur-
inoceptor agonist 2MeSATP neither inhibited nor activated
adenylyl cyclase in these cells. Lack of effect of the expressed
human P2YI-purinoceptor on cyclic AMP accumulation is an
important observation in face of the existence of a P2Y-pur-
inoceptor on C6 rat glioma cells that inhibits adenylyl cyclase
but has no effect on inositol lipid hydrolysis or Ca2+ mobiliza-
tion. This specificity ofcoupling of P2Y-purinoceptors to second
messenger signalling cascades is not an artifact of the existence
of signalling proteins in C6 glioma cells that are not present in
1321N1 cells or vice versa, since the human P2YI-purinoceptor
retained fidelity of coupling to the inositol lipid signalling
pathway when expressed in C6 glioma cells. Pharmacological
differences between the phospholipase C-linked P2YI-pur-
inoceptor and the yet-to-be-cloned adenylyl cyclase-linked P2y-
purinoceptor were maintained in C6 cells expressing both of
these receptors. For example, we previously reported that the P2-
purinoceptor antagonist, PPADS, competitively antagonizes
the avian P2YI-purinoceptor, but has no effect on the adenylyl
cyclase-linked P2Y-purinoceptor endogenously expressed in C6
cells (Boyer et al., 1993; 1994). In C6 cells engineered to express
both of these receptors, the inositol phosphate response to
2MeSATP was blocked by PPADS, whilst the cyclic AMP re-
sponse was unaffected. Differences in agonist potencies for in-
ositol phosphate and cyclic AMP responses identified from our
previous studies of the avian and C6 cell receptors also were
observed in C6 cells expressing both receptors. These data
strongly support our previous contention that a novel P2Y-like
purinoceptor exists on C6 glioma cells that differs in pharma-
cological and biochemical properties from the previously cloned
phospholipase C-linked P2Y,-purinoceptor. Cloning of nucleo-
tide sequence encoding this Gi-linked P2-purinoceptor is an
important goal, particularly since this would provide the first
receptor sequence for what may prove to be a larger class of G,-
linked P2-purinoceptors.
Henderson et al. (1995) recently reported the cloning and
expression of a cDNA that apparently encodes the bovine
homologue of the P2Y,-purinoceptor. However, the functional
receptor expressed from this cDNA exhibited a different
pharmacological selectivity with three agonists from that pre-
viously reported from our laboratory for the cloned expressed
turkey P2M1-purinoceptor. ADP and 2MeSATP were equipo-
tent (EC50 = 30 nM) and ATP was considerably less potent and
less efficacious for activation of the bovine receptor (Hender-
son et al., 1995). The 86% sequence similarity between the
bovine and avian sequences led Henderson et al. (1995) to
conclude tentatively that the bovine and avian receptors are
species homologues and that differences in apparent pharma-
cological selectivity were probably explained by the different
cell types (Jurkat versus 1321N1 cells) used for stable expres-
sion and the different second messenger responses (Ca2+ mo-
bilization versus inositol phosphate accumulation, Filtz et al.,
1994) used in the two studies to monitor receptor activation.
The extensive comparison reported in the current work of
pharmacological selectivities of the turkey and human re-
ceptors expressed in the same cell type and assayed under
identical conditions supports the conclusion that the avian and
human receptors are species homologues that exhibit no ap-
parent differences either in their second messenger signalling
cascade specificity or in their pharmacological selectivities.
These relative agonist potencies also should be an accurate
reflection of relative affinities for the human and turkey P2y1-
purinoceptor since extensive analyses have failed to reveal any
evidence for agonist hydrolysis during the assays that underlie
the determination of these drug potencies.
In summary, the nucleotide sequence encoding the human
P2Y1-purinoceptor has been cloned and stably expressed.
Therefore, we are now in a position to establish the extent to
which the P2YI-purinoceptor accounts for P2y-purinoceptor-
mediated regulation of physiological responses in mammalian
tissues. The availability of a single human P2Y-purinoceptor of
defined structure in a preparation that allows simple tests of
receptor agonist and antagonist activities should be useful in
identifying increasingly specific P2Y-purinoceptor agonists and
antagonists.
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